Evidence map›Paper›PMID 31857446›Full record

ArticleThe oncologist2020

A Pilot Feasibility Study of Yttrium-90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver Metastases.

Chongkai Wang, John Park, Ching Ouyang, Jeff A Longmate, Michael Tajon, Joseph Chao, Dean Lim, Jaideep Sandhu, Hongwei Holly Yin, Raju Pillai and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 3 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Trial
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Immune checkpoint inhibition: a future guided by radiology.The British journal of radiology · 2023
    Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Chongkai WangDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
John ParkDepartment of Diagnostic Radiology, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Ching OuyangCenter for Informatics, Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, California, USA.
Jeff A LongmateDivision of Biostatistics, Beckman Research Institute of the City of Hope, Duarte, California, USA.
Michael TajonClinical Trial Office, City of Hope National Medical Center, Duarte, California, USA.
Joseph ChaoDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Dean LimDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Jaideep SandhuDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Hongwei Holly YinDepartment of Pathology, City of Hope National Medical Center, Duarte, Calilfornia, USA.
Raju PillaiDepartment of Pathology, City of Hope National Medical Center, Duarte, Calilfornia, USA.
Maricel C GozoDepartment of Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte, California, USA.
Christian AvalosDepartment of Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte, California, USA.
Colt A EgelstonDepartment of Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte, California, USA.
Peter P LeeDepartment of Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte, California, USA.
Marwan FakihDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
City of Hope · USCity Of Hope National Medical Center · USBeckman Research Institute

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
NCI NIH HHS P30 CA033572
6 · The paper itself

Abstract

lessons learnedRadioembolization with yttrium-90 resin microspheres can be combined safely with full doses of durvalumab and tremelimumab in patients with metastatic colorectal cancer. Regional radioembolization with yttrium-90 resin microspheres did not result in any hepatic or extrahepatic responses to a combination of durvalumab and tremelimumab. The lack of immunomodulatory responses to yttrium-90 on biopsies before and after treatment rules out a potential role for this strategy in converting a "cold tumor" into an "inflamed," immune responsive tumor.

backgroundPD-1 inhibitors have been ineffective in microsatellite stable (MSS) metastatic colorectal cancer (CRC). Preclinical models suggest that radiation therapy may sensitize MSS CRC to PD-1 blockade.

methodsPatients with MSS metastatic CRC with liver-predominant disease who progressed following at least one prior line of treatment were treated with yttrium-90 (Y90) radioembolization to the liver (SIR-Spheres; Sirtex, Woburn, MA) followed 2-3 weeks later by the combination of durvalumab and tremelimumab. A Simon two-stage design was implemented, with a planned expansion to 18 patients if at least one response was noted in the first nine patients.

resultsNine patients enrolled in the first stage of the study, all with progressive disease (PD) during or after their first two cycles of treatment. Per preplanned design, the study was closed because of futility. No treatment-related grade 3 or greater toxicities were recorded. Correlative studies with tumor biopsies showed low levels of tumor-infiltrating lymphocyte (TIL) infiltration in tumor cancer islands before and after Y90 radioembolization.

conclusionY90 radioembolization can be added safely to durvalumab and tremelimumab but did not promote tumor-directed immune responses against liver-metastasized MSS CRC.

Indexed as

Colorectal NeoplasmsEmbolization, TherapeuticLiver NeoplasmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedFeasibility StudiesHumansMicrosatellite RepeatsTreatment OutcomeYttrium RadioisotopesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizeddurvalumabtremelimumabYttrium-90Yttrium Radioisotopes

Identifiers

PMID31857446
PMCPMC7216435
OpenAlexW2996655902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.